NCT00757029

Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Hallym University Medical Center · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Conditions

• Attention Deficit Disorder With Hyperactivity
• Methylphenidate
• Pharmacogenetics

Interventions

Type	Name	Description
GENETIC	norepinephrine transporter polymorphism,	OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism

Timeline

• Start date: 2005-10-01
• Primary completion: 2008-08-01
• Completion: 2010-08-01
• First posted: 2008-09-22
• Last updated: 2011-10-05

Locations

1 site across 1 country: South Korea